Fixed combinations in POAG and OHT patients

Article

An overview of trials comparing topical medical therapies

Intraocular pressure (IOP) is currently the only modifiable risk factor for the progression of the disease, but there is no ideal IOP for all patients. The risk profile of each single patient should be carefully evaluated before deciding treatment algorithm.8 The initial treatment of glaucoma is typically to prescribe a single ocular hypotensive medication to reduce the IOP. However, over time, the pressure may again become elevated requiring the addition of a second medication. Approximately 40% of subjects with ocular hypertension require two or more topical medications to control IOP.9,10 When target IOP is not achieved with a single agent, combined therapy using drugs with different mechanisms of action is recommended.8

Multiple local therapies may be associated with more local and systemic side effects11 because of increased exposure to preservatives, with a higher incidence of ocular signs and symptoms and poor compliance.12–14 Fixed combinations (FCs) of two anti-glaucoma drugs have been formulated to obtain a greater reduction in IOP than that which can be achieved using single agents, to allow fewer doses, and to ensure less exposure to preservatives.11

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Osamah Saeedi, MD, MS, at ARVO 2024
Dr Nir Shoham Hazon, Director, Miramichi EyeNB Centre of Excellence, New Brunswick, Canada
© 2025 MJH Life Sciences

All rights reserved.